Zdrowie i gospodarka · 24/06/2024
FDA Clears INVEGA Extended-Release Tablet for Continued Approval
The FDA has determined that INVEGA (paliperidone) extended-release tablet, 1.5mg, was not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) that refer to the product.